Oncopeptides AB (LTS:0RN4) 3-Year EBITDA Growth Rate : 53.40% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB 3-Year EBITDA Growth Rate?

Oncopeptides AB's EBITDA per Share for the three months ended in Mar. 2024 was kr-0.52.

During the past 3 years, the average EBITDA Per Share Growth Rate was 53.40% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 26.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Oncopeptides AB was 53.40% per year. The lowest was -95.70% per year. And the median was -58.20% per year.

Competitive Comparison of Oncopeptides AB's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Oncopeptides AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncopeptides AB's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncopeptides AB's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncopeptides AB's 3-Year EBITDA Growth Rate falls into.

Oncopeptides AB 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Oncopeptides AB (LTS:0RN4) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Oncopeptides AB 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (LTS:0RN4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (LTS:0RN4) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ONCO:Sweden OND:Germany

Address

Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53

Website

https://www.oncopeptides.com

Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.

Oncopeptides AB (LTS:0RN4) Headlines

No Headlines